D. Boral Capital Reiterates Buy Rating for CollPlant Biotechnologies (NASDAQ:CLGN)

D. Boral Capital restated their buy rating on shares of CollPlant Biotechnologies (NASDAQ:CLGN) in a report released on Wednesday morning,Benzinga reports. They currently have a $14.00 price objective on the stock.

Several other research firms also recently weighed in on CLGN. EF Hutton Acquisition Co. I raised CollPlant Biotechnologies to a “strong-buy” rating in a report on Monday, August 5th. HC Wainwright reiterated a “buy” rating and issued a $11.00 price objective on shares of CollPlant Biotechnologies in a research note on Wednesday, August 21st.

CollPlant Biotechnologies Price Performance

Shares of NASDAQ:CLGN opened at $4.21 on Wednesday. CollPlant Biotechnologies has a 12 month low of $3.31 and a 12 month high of $6.99. The firm has a market capitalization of $48.23 million, a P/E ratio of -2.76 and a beta of 0.44. The company’s fifty day moving average price is $4.31 and its 200 day moving average price is $4.85.

Institutional Investors Weigh In On CollPlant Biotechnologies

Several hedge funds have recently made changes to their positions in CLGN. Benjamin Edwards Inc. purchased a new stake in CollPlant Biotechnologies during the 3rd quarter valued at approximately $112,000. Villere ST Denis J & Co. LLC raised its stake in shares of CollPlant Biotechnologies by 24.4% during the third quarter. Villere ST Denis J & Co. LLC now owns 484,867 shares of the company’s stock worth $2,407,000 after purchasing an additional 95,000 shares during the last quarter. Finally, Pinnacle Associates Ltd. raised its stake in shares of CollPlant Biotechnologies by 6.4% during the second quarter. Pinnacle Associates Ltd. now owns 564,360 shares of the company’s stock worth $2,805,000 after purchasing an additional 33,905 shares during the last quarter. Institutional investors and hedge funds own 21.69% of the company’s stock.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.